Leaders in Disease Management were evaluated by their commitment to the disease management discipline, their program results, their innovation and their thought leadership. Watch for the Special Issue of Managed Healthcare Executive, available beginning September 7, 2008! George Bennett, Health Dialog Services Corp.Paul Bluestein, ConnectiCareJohn Castiglia, Premera Blue CrossTerry Crowson, HealthPartnersD.W. Edington, University of Michigan Health Management Research CenterJay Feldstein, AmeriHealth Mercy Family of Cos.Judith Frampton, Harvard Pilgrim Health CareRon Geraty, Alere Medical Inc.Bob Ihrie, Lowe's Cos., Inc.Joan Kennedy, WellpointBarry Lachman, Parkland Community Health PlanBen Leedle, HealthwaysHarlan Levine, Towers PerrinDijuana Lewis, Comprehensive Health Solutions Business Unit of WellpointAriel Linden, Linden Consulting GroupPam Menard, Independent HealthTracey Moorhead, DMAA: The Care Continuum AllianceDavid Nash, Jefferson Medical CollegeGordon Norman, Alere Medical Inc.Michael Norris, Great-West HealthcareHarold Picken, BCBS Rhode IslandDavid Plocher, Blue Cross MinnesotaJim Prochaska, Cancer Prevention Research CenterMichael Quilty, Matrix Medical NetworkEmad Rizk, McKesson Health SolutionsRichard Safeer, CareFirst BlueCross BlueShieldChris Selecky, LifemastersKara Trott, Quantum Health Inc.
A complete list of leaders and their respective titles and affiliations is noted here.
DC Roundtable: Patrick Cooney of The Federal Group Drops the Latest on PBM Legislation in Washington
April 11th 2024In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.
Listen
Providing Access to Rezdiffra for NASH and the Therapies to Come | AMCP 2024
April 16th 2024The pipeline for NASH treatments is robust, with six therapies in phase 3 development. Speakers at the annual AMCP meeting discuss Rezdiffra, the first drug approved specifically for NASH, and how to think about coverage issues.
Read More